Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral PRX-112 Dose Escalation in Gaucher Disease
NCT02107846Phase 2Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of taliglucerase alfa in Gaucher disease (GD), sponsored by Protalix BioTherapeutics. Started Apr 2014; status: completed.
02
Drugs
taliglucerase alfa
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on NCT02107846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107846.